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Background: Taxane is one of the first line treatments of lung cancer. In order to identify novel single nucleotide
polymorphisms (SNPs) that might contribute to taxane response, we performed a genome-wide association study
(GWAS) for two taxanes, paclitaxel and docetaxel, using 276 lymphoblastoid cell lines (LCLs), followed by
genotyping of top candidate SNPs in 874 lung cancer patient samples treated with paclitaxel.
Methods: GWAS was performed using 1.3 million SNPs and taxane cytotoxicity IC50 values for 276 LCLs. The
association of selected SNPs with overall survival in 76 small or 798 non-small cell lung cancer (SCLC, NSCLC)
patients were analyzed by Cox regression model, followed by integrated SNP-microRNA-expression association
analysis in LCLs and siRNA screening of candidate genes in SCLC (H196) and NSCLC (A549) cell lines.
Results: 147 and 180 SNPs were associated with paclitaxel or docetaxel IC50s with p-values <10-4 in the LCLs,
respectively. Genotyping of 153 candidate SNPs in 874 lung cancer patient samples identified 8 SNPs (p-value
< 0.05) associated with either SCLC or NSCLC patient overall survival. Knockdown of PIP4K2A, CCT5, CMBL, EXO1,
KMO and OPN3, genes within 200 kb up-/downstream of the 3 SNPs that were associated with SCLC overall survival
(rs1778335, rs2662411 and rs7519667), significantly desensitized H196 to paclitaxel. SNPs rs2662411 and rs1778335
were associated with mRNA expression of CMBL or PIP4K2A through microRNA (miRNA) hsa-miR-584 or hsa-miR-
1468.
Conclusions: GWAS in an LCL model system, joined with clinical translational and functional studies, might help us
identify genetic variations associated with overall survival of lung cancer patients treated paclitaxel.
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Taxanes are an important class of chemotherapeutic
agents that disrupt the dynamics of microtubules by en-
hancing tubulin assembly and inhibiting depolymerisa-
tion [1]. Two taxanes, paclitaxel (TaxolW) and docetaxel
(TaxotereW), are widely used for a broad spectrum of
cancers, including lung cancer, one of the most common* Correspondence: wang.liewei@mayo.edu
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reproduction in any medium, provided the orcancer types and the leading cause of cancer mortality in
the US in 2012 [2,3]. However, as a first-line therapy for
non-small cell lung cancer (NSCLC) and a second-line
therapy for small cell lung cancer (SCLC) [4,5], large
inter-individual variations have been observed in re-
sponse to taxane therapy, in both efficacy and toxicity.
One major side effect of taxanes, especially paclitaxel, is
peripheral neuropathy, which limits dose escalation for
optimal treatment with taxanes in the clinic [6]. Re-
sponse rates for a single treatment with paclitaxel in
patients with advanced NSCLC or extensive stage of
SCLC are 24% and 34%, respectively [7]. Overall response. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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17-32%, and the incidence of grade 3/4 peripheral neur-
opathy was 1-13% in advanced NSCLC [8].
A great deal of effort has been devoted to the identifica-
tion of biomarkers for response to these agents. Genetic
polymorphisms in CYP3A4, ABCB1, ERCC1, ERCC2, and
XPD1 were found to be associated with inter-individual
differences in taxane response in NSCLC patients [9-11],
while other variants in CYP2C8, CYP3A5 and ABCB1
were related to variability in taxane-mediated neurotox-
icity [12,13]. These observations may relate to the effect of
genetic polymorphisms on the alteration of either taxane
pharmacokinetic or pharmacodynamic profiles through
influence on gene expression or enzyme activities [14,15].
In addition, a genome-wide linkage study using 427 lym-
phoblastoid cell lines (LCLs) from 38 Centre d’Etude du
Polymorphisme Humain (CEPH) reference pedigrees
identified two loci, 5q11-21 and 9q13-22, associated with
docetaxel-induced cytotoxicity [16]. Another study using
breast cancer cell lines showed that increasing ABCC3 ex-
pression was highly associated with paclitaxel resistance
[17]. Recently, a clinical GWAS with 1040 patients treated
with paclitaxel identified 3 SNPs located in the EPHA5,
FGD4 and NDRG1 genes that were associated with
peripheral neuropathy [18]. All of these results suggest
that genetic variation plays an important role in inter-
individual variation in taxane response.
In the present study, we tested the hypothesis that
genetic variation may contribute to inter-individual vari-
ation in overall survival of lung cancer patients treated
with paclitaxel-based therapy. As a first step to identifyFigure 1 Schematic diagram of the experimental strategy. Genome-w
using 1.3 million SNPs. 147 SNPs were associated with paclitaxel IC50 with
taxanes with p-values < 10-3. Those SNPs were genotyped in 874 lung can
found to be consistently associated with both paclitaxel IC50 in LCLs and l
SNPs were functionally validated using lung cancer cell lines.additional novel quantitative trait loci (QTL) contribut-
ing to taxane response, we performed pharmacogenomic
studies with both paclitaxel and docetaxel using a
genome-wide association (GWA) approach with 276
LCLs, a cell line model system that has been used suc-
cessfully in many previous pharmacogenomic studies to
identify genetic variation related to drug or radiation re-
sponse phenotypes [19-21]. We then genotyped 874
Caucasian lung cancer patients (76 SCLC and 798
NSCLC) for the 170 most significant candidate SNPs
identified during the association studies with the 276
LCLs. Eight SNPs were found to be consistently asso-
ciated with both paclitaxel IC50 in LCLs and overall sur-
vival in SCLC or NSCLC patients. Finally, 11 candidate
genes, located within 200 kb up-/downstream of those 8
SNPs, were subjected to functional validation in lung
cancer cell lines by using siRNA screening and MTS
assays (Figure 1). In addition, we also performed SNP-
expression association analysis and integrated SNP-
miRNA-expression association analysis using those 8




As described in our previous publication [21], EBV-
transformed LCLs from 96 African-American (AA), 96
Caucasian-American (CA), and 96 Han Chinese-American
(HCA) unrelated subjects (sample sets HD100AA,
HD100CAU, HD100CHI) were purchased from the Coriell
Cell Repository (Camden, NJ). These samples had beenide association studies were performed for paclitaxel or docetaxel IC50
p-values < 10-4 and 76 SNPs were associated with IC50 values for both
cer patients treated with paclitaxel-based chemotherapy. 8 SNPs were
ung cancer overall survival. Eleven genes which were close to those 8
Table 1 Clinical characteristics of 874 lung cancer
patients treated with paclitaxel-based chemotherapy
Description of patients who received taxane-based chemotherapy
Total (N = 874)
Age at Diagnosis
Mean (SD) 61.8 (10.4)





Never smokers 158 (18.1%)
Former smokers 428 (49%)
Current smokers 273 (31.2%)






Stage I and II 153 (17.5%)
Stage III 328 (37.5%)
Stage IV 317 (36.3%)
Histologic cell type
Adenocarcinoma/bronchioloalveolar carcinoma 465 (53.2%)
Squamous cell carcinoma 162 (18.5%)
Small cell carcinoma 76 (8.5%)
Large cell carcinoma 28 (3.2%)
Mixed and unspecified NSCLC 131 (15.0%)
Others 12 (1.4%)
Tumor differentiation grade
Well differentiated 76 (8.7%)
Moderately differentiated 332 (38.0%)
Poor/undifferentiated 395 (45.2%)
Nongradable or unknown 71 (8.1%)
Surgery, chemotherapy, radiation
Chemotherapy 238 (27.2%)
Surgery & chemotherapy 157 (18%)
Radiation & chemotherapy 311 (35.6%)
Surgery & radiation & chemotherapy 168 (19.2%)
Stage for NSCLC is described on the basis of the tumor-node-metastasis
classification. The small cell lung cancer stage is described as suggested by
the American Cancer Society as either “Extensive” or “Limited.” Abbreviations:
SCLC, small cell lung cancer, NSCLC, non-small cell lung cancer.
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ten consent for their experimental use. This study was
reviewed and approved by Mayo Clinic Institutional Review
Board. Human SCLC cell line H196 and NSCLC cell line
A549 were obtained from the American Type Culture Col-
lection (Manassas, VA). LCLs were cultured in RPMI 1640
medium (Mediatech, Manassas, VA) supplemented with
15% heat-inactivated Fetal Bovine Serum (FBS) (Media-
tech). H196 and A549 cell lines were cultured in RPMI
1640 medium containing 10% FBS.
Lung cancer patient samples
A total of 874 lung cancer patients treated with taxane-
based therapy, including 76 SCLC and 798 NSCLC, were
identified and enrolled between 1997 and 2008 at the
Mayo Clinic (Rochester, MN). Details regarding clinical
characteristics of these patients, patient enrollment, and
data collection procedures were described previously
[22,23]. Briefly, each case was identified through the
Mayo Clinic pathologic diagnostic (Co-Path) system.
After obtaining written informed consent, blood samples
were collected from patients. The characteristics of
patients were abstracted from the medical record, in-
cluding demographics, lung cancer pathology, anatomic
site, and types and timing of treatment and chemothera-
peutic agents. The clinical staging and recurrence or
progression data were determined by results from avail-
able chest radiography, computerized tomography, bone
scans, position emission tomography scans, and mag-
netic resonance imaging. All patients were actively fol-
lowed up during the initial six months after diagnosis,
with subsequent annual follow-up by mailed question-
naires and annual verification of the patients’ vital status.
These research protocols were also approved by the
Mayo Clinic Institutional Review Board.
In addition to paclitaxel, many patients were also trea-
ted with radiation therapy and/or surgery, as well as 4
other classes of anticancer drugs: platinum agents, gem-
citabine, EGFR inhibitors and etoposide. Detailed infor-
mation is listed in Table 1.
Cell proliferation assay
Paclitaxel and docetaxel were purchased from Sigma-
Aldrich (Milwaukee, WI). Drugs were dissolved in DMSO
and aliquots of stock solutions were frozen at −80°C. Cell
proliferation assays were performed in triplicate at each
drug concentration. Specifically, 90 μl of cells (5 × 105
cells/ml) were plated into each well of 96-well plates
(Corning, Lowell, MA) [19] and were treated with 10 μl of
paclitaxel or docetaxel at final concentrations of 0, 0.1, 1,
10, 15, 20, 100, 1000, 5000 nmol/L for paclitaxel and 0,
0.1, 1, 5, 7.5, 15, 100, 1000, 10000 nmol/L for docetaxel.
72 hours later, 20 μl of CellTiter 96 AQueous Non-
Radioactive Cell Proliferation Assay solution (PromegaCorporation, Madison, WI) were added to each well and
incubated for an additional 3 hours. Plates were then read
in a Safire2 microplate reader (Tecan AG, Switzerland).
Experiments were successfully performed for 276 LCLs
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the lung cancer cell lines were conducted in a similar fash-
ion except paclitaxel was added after the cells were incu-
bated overnight. The final concentrations of paclitaxel
were 0, 0.1, 1, 10, 25, 50, 100, 1000, 5000 nmol/L.
Genome-wide SNPs in LCLs
Illumina HumanHap 550 K and 510S BeadArrays, con-
taining 561,298 and 493,750 SNPs respectively, were
used to genotype DNA samples from the LCLs in the
Genotype Shared Resource (GSR) at Mayo Clinic,
Rochester, MN. Publicly available Affymetrix SNP Array
6.0 Chip SNP data were also obtained for the same cell
lines, which assayed 643,600 SNPs not covered on the
Illumina BeadChips. The genotyping data were used in
our previous studies [20,21] and are public available
from NCBI Gene Expression Omnibus under Super-
Series accession No. GSE24277. SNPs that deviated from
Hardy-Weinberg Equilibrium (HWE) based on the mini-
mum p-value from an exact test for HWE [24] and the
stratified test for HWE [25] (p-values < 0.001); SNPs
with call rates < 95%; or SNPs with minor allele frequen-
cies (MAFs) < 5% were removed from the analysis.
Expression array assays in LCLs
Total RNA was extracted from each of the cell lines
using Qiagen RNeasy Mini kits (QIAGEN, Inc.). RNA
quality was tested using an Agilent 2100 Bioanalyzer, fol-
lowed by hybridization to Affymetrix U133 Plus 2.0
Gene-Chips. The expression array data was used in our
previous studies [19-21] and is public available from
NCBI Gene Expression Omnibus under SuperSeries ac-
cession no. GSE24277 and accession No. GSE23120.
MiRNA array assays in LCLs
Total RNA including miRNA from each LCL was
extracted using mirVana™ miRNA isolation kit (Ambion,
Austin, TX). RNA quality was measured using Ribo-
GreenW RNA Quantitation Kit (Molecular Probes, Eu-
gene, OR) in an Agilent 2100 Bioanalyzer. Like described
before [26], miRNA array assay was performed using Illu-
mina’s human miRNA BeadArray according to the work-
flow on Illumina website. Briefly, total RNA were
polyadenylated and converted to cDNA using a biotiny-
lated oligo-dT primer with a universal PCR sequenced at
its 5' end, followed by the annealing and extension of
miRNA-specific oligonucleotide pool (MSO), which con-
sists of a universal PCR priming site at the 5' end, an ad-
dress sequence complementary to a capture sequence on
the BeadArray and a microRNA-specific sequence at the
3' end. Then cDNA was amplified and subsequently hybri-
dized to Illumina Sentrix Array Matrix (SAM)-Bead
microarray chips. The SAMs were imaged using an Illu-
mina BeadArray Reader, and microarray data wereprocessed and analyzed using Illumina BeadStudio version
3.1.1. Probe-samples with a signal that was significantly
higher than the background detection level were retained
(at a significance level of 0.01). Probes with missingness
≥ 80% and individuals with missingness ≥ 50% were
removed. The log2 expression levels were adjusted for an
observed plate effect; there was no evidence of differential
expression by ethnicity. Probes which had expression
levels with standard deviation < 0.40 were deemed insuffi-
ciently variable to be informative, and potentially reflected
only a background level of intensity. These were removed,
leaving a final set of 226 probes and 282 individuals.
Genotyping in lung cancer patients
The 170 top SNPs selected from our taxane GWAS in
LCLs were used to genotype 874 lung cancer patient
DNA samples using a custom-designed Illumina Golden
Gate platform at Mayo Clinic, Rochester, MN. The con-
cordance rate among three genomic control DNA sam-
ples (CEPH family trio, Coriell Institute) present in
duplicate on each 96 well plate was 100%. After remov-
ing the subjects with call rates < 90%, SNPs with call
rates < 95% and monomorphic SNPs, 153 SNPs (90%)
were used for the analysis.
Transient transfection and RNA interference
siRNA pools for candidate genes and negative control
were purchased from Dharmacon (Chicago, IL). Reverse
transfection of siRNA was performed in 96-well plates
with a mixture of either non-small cell lung cancer, A549
cells, or small cell lung cancer, H196 cells and 0.3 μL of
lipofectamine™ RNAi-MAX reagent (Invitrogen), as well
as 30 nmol/L siRNA pools.
Real-time quantitative reverse transcription-PCR
(qRT-PCR)
Total RNA was isolated from cultured cells transfected
with negative control or specific siRNA pools using
Quick-RNA™ MiniPrep kit (Zymo Research, Orange,
CA), followed by qRT-PCR performed with the Power
SYBRW Green RNA-to-CT
™ 1-Step Kit (AB Foster CA). Spe-
cifically, primers purchased from QIAGEN were used to
perform qRT-PCR using the Stratagene Mx3005P Real-
Time PCR detection system (Stratagene). All experi-
ments were performed with beta-actin as an internal
control.
Statistical methods
Genome-wide analysis in LCLs
The taxane cytotoxicity phenotype IC50, indicating the
drug concentration which inhibits half of maximal cell
growth, was calculated based on the Brain–Cousen
model [27,28] using the R package “drc” for each indi-
vidual cell line for each drug separately. As described
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values, the Van der Waerden (rank) transformed IC50
and SNPs were adjusted for gender, race and population
stratification. To perform the SNP and mRNA gene ex-
pression associations, the mRNA expression array data
were normalized using GCRMA, log2 transformed, and
adjusted for gender, race, population stratification, and
batch effect [29]. For miRNA and mRNA gene expres-
sion analyses, the normalized, log2 transformed mRNA
expression array data were only adjusted for gender,
race, and batch, while the miRNA expression array data
were transformed using a Van der Waerden (rank) trans-
formation and adjusted for gender, race and batch. The
miRNA and SNP associations used genotype and Van
der Waerden (rank) transformed miRNA expression
data that were both adjusted for gender, race and popu-
lation stratification.
To quantify the association of the adjusted IC50 pheno-
type with genome-wide SNPs (imputed and genotyped),
Pearson correlations were calculated with adjusted SNPs.
Likewise, the associations of SNPs with mRNA expression,
SNPs with miRNA expression, as well as miRNA with
mRNA expression were quantified by Pearson correlations
using adjusted SNPs, mRNA and miRNA expression.
SNPs in regions of interest were imputed with MACH
v1.0 [30] using the HapMap Release 22 (Phase II) phased
haplotype data as the reference. Specifically, SNPs for AA
were imputed using both CEU (Utah residents with
Northern and Western European ancestry from the CEPH
collection) and YRI (Yoruba in Ibadan, Nigeria) data,
SNPs for CA were imputed based on CEU data, and SNPs
for HCA were imputed based on the CHB (Han Chinese
in Beijing, China) and JPT (Japanese in Tokyo, Japan)
data.
Clinical lung cancer patient analysis
The overall survival time was used as the primary end-
point, defined as the time from lung cancer diagnosis to
either death or the last known date alive. Patients known
to be alive were censored at the time of last contact. To
test for the effect of SNP genotypes on overall survival,
we used the Cox regression model that included the
effects of a SNP genotype dosage (count of minor allele).
A total of 153 SNPs were included in this analysis, and
the association was performed for NSCLC and SCLC
separately because of the significant differences between
the two diseases. To correct for multiple testing of the
153 SNPs in the two lung cancer subsets (a total of 306
tests), a Bonferroni corrected p-value threshold of
0.0001 was used to determine statistically significant
associations. To determine whether associations with
SNPs should be adjusted for the clinical covariates of
age at diagnosis, gender, smoking status, disease stage,
and treatment, backward selection was performed. Thedisease stage was included in the final multivariate Cox-
regression model as it was significantly associated with
the overall survival of lung cancer patients. The disease
stage was divided into five categories: small cell lung
cancer with stages limited versus extensive; NSCLC with
stages I + II, versus III versus IV. Since the effect of the
SNPs on overall survival might be influenced by histo-
logic subtypes among NSCLC patients, the association
of three major histologic cell types (Adenocarcinoma/
bronchioloalveolar carcinoma, squamous cell carcinoma
and mixed and unspecified NSCLC) with overall survival
was also tested with adjustment of disease stage and no
significant association was found (p-value = 0.86). We
used 0.05 as a cutoff for p-values (not adjusted for mul-
tiple testing) to select SNPs/genes for further functional
validation.
Results
Paclitaxel and docetaxel cytotoxicity in LCLs
As both taxanes are used in clinical practice and share
common mechanisms of action, cytotoxicity assays were
performed for both drugs to determine the range of vari-
ation in individual drug response. We used IC50 as a
phenotype to indicate the drug sensitivity for each cell
line. The range of IC50 values for paclitaxel and doce-
taxel were 3.98-21.36 nmol/L and 1.54-13.32 nmol/L, re-
spectively, and the median values were 9.35 nmol/L and
4.29 nmol/L. There was no evidence of differences in
IC50 between genders (p = 0.82, 0.71) or races (p = 0.45,
0.14) in the paclitaxel and docetaxel experiments,
respectively.
Genome-wide SNP associations with IC50 values for two
taxanes
As described previously [21], after the quality control of
all SNPs genotyped with the Illumina HumanHap 550 K,
510S BeadChips and Affymetrix SNP Array 6.0 Chip, ap-
proximately 1.3 million SNPs were used for the associ-
ation analyses between genome-wide SNPs and IC50
values for paclitaxel and docetaxel to identify SNPs that
might contribute to variation in drug cytotoxicity pheno-
types. As shown in Figure 2A-B and Additional file 1:
Tables S1–S2, none of the SNPs remained significant
after Bonferroni correction. The most significant SNPs
associated with paclitaxel or docetaxel IC50, rs10521792
and rs6044112, had p-values of 2.04 × 10-7 and 6.90 × 10-7,
respectively. The rs10521792 SNP is 300 kb up-
stream from the 50-end of the FGF13 gene and the
rs6044112 SNP is within an intron of C20orf23. For
paclitaxel, 147 SNPs within or near 88 unique genes
had p-values < 10-4 for association with IC50, while
docetaxel had 180 SNPs within 102 unique genes
meeting these criteria. One thousand and fifteen and 1736
SNPs had association p-values < 10-3 for paclitaxel and
Figure 2 1.3 million genome-wide SNPs associations with taxane IC50s in LCLs. (A and B) Genome-wide SNP association with paclitaxel (A)
or docetaxel IC50 values (B). The y-axis represents -log10(p-values) for the association of each SNP with paclitaxel/docetaxel IC50 values. SNPs are
plotted on the x-axis based on their chromosomal locations. A p-value of 10-4 is highlighted with a red line. (C) The number of overlapping SNPs
associated with IC50s for both paclitaxel and docetaxel with p-value < 10-3.
Niu et al. BMC Cancer 2012, 12:422 Page 6 of 13
http://www.biomedcentral.com/1471-2407/12/422docetaxel, respectively (Additional file 1: Tables S1–S2,
Figure 2C). As paclitaxel and docetaxel belong to the same
class of antimicrotubule agents, we also compared the set
of SNPs with p-value < 10-3 between these two drugs, of
which 76 SNPs in 55 genes were in common between the
top set of SNPs for both drugs (Additional file 1: Table S3,
Figure 2C).Association study for lung cancer patients treated with
taxane-based therapy
Taxanes are one of the most commonly used chemother-
apeutic agents in the treatment of lung cancer patients,
either alone or in combination with other anticancer
drugs. We wanted to determine whether the top candi-
date SNPs identified during our GWAS using the cell
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vival of patients treated with taxanes. We took advantage
of 874 germline DNA samples collected from lung can-
cer patients treated with paclitaxel at Mayo Clinic, in-
cluding 76 SCLC and 798 NSCLC with well characterized
phenotypes, to test this hypothesis. Detailed patient char-
acteristics are described in Table 1.
Since almost all of the 874 lung cancer patient
included in the study were treated with paclitaxel, we
selected the top SNPs identified from our paclitaxel
GWAS in LCLs for genotyping in those 874 lung cancer
patients, including 147 SNPs associated with paclitaxel
IC50 with p-value < 10-4 and 76 “overlapping SNPs”
associated with both taxane IC50s with p-value <10-3
(Figure 1). After removing SNPs with lower Illumina de-
sign scores and SNPs with absolute linkage disequilib-
rium (r2 = 1), 170 SNPs were genotyped using the
Illumina Golden Gate platform. For quality control, we
excluded SNPs with low call rate and monomorphic
SNPs, which resulted in 153 SNPs being analyzed
(Additional file 1: Table S4). As shown in Table 2, the
Cox regression analysis indicated that 11 SNPs were
associated with SCLC or NSCLC overall survival with
p-value < 0.05, although none of them were statisticallyTable 2 8 SNPs associated with paclitaxel response in both LC
SNP Lung cancer patients LCL











rs7519667 — — 0.028 0.543 0.178 2.71E-
05
−0.261 —
rs10193067 — — 0.039 0.372 0.043 3.61E-
05
0.254 —
rs2700868 0.028 1.193 — — 0.157 6.56E-
05
0.248 —
rs2662411 — — 0.039 0.666 0.417 6.36E-
05
−0.246 —
rs1106697 0.016 1.237 0.007 1.875 0.106 7.00E-
05
0.245 —
rs1778335 — — 0.019 1.602 0.308 6.04E-
05
0.248 —
rs11629576 — — 0.011 0.637 0.447 6.-
0577E
0.245 —
















11 of 153 SNPs were associated with SCLC or NSCLC overall survival with p-value <
had poor survival. In other words, the same SNP would be expected to be associate
association direction for clinical overall survival with that of the LCL results, 8 out o
phenotypes. The 3 SNPs showed opposite association directions were rs10193067,significant after Bonferroni correction. The most signifi-
cant SNPs, rs1106697 and rs11079337, were associated
with SCLC or NSCLC overall survival with p-values of
0.007. SNP rs1106697, which was located on chromo-
some 7 and with a MAF of 0.106, was associated with
overall survival in both NSCLC (p = 0.016, HR = 1.237)
and SCLC (p = 0.007, HR = 1.875) patients. The hazard
ratio (HR) > 1 means that patients carrying the minor al-
lele had poor survival. In other words, the same SNP
would be expected to be associated with higher IC50
values in our LCLs, and the cells carrying this SNP
would be expected to be more resistant to paclitaxel.
Therefore, we compared the association direction for
clinical overall survival with that of the LCL results. We
found that 8 out of 11 SNPs showed concordant associ-
ation directions between the two phenotypes (Table 2).
Follow-up analyses
Imputation analysis in LCLs
In order to identify the causal SNPs or additional SNPs
that were in strong linkage with the causal SNPs con-
tributing to paclitaxel response, we imputed SNPs based
on HapMap data using the genotyping results of LCLs









— 0.308 1 239,951,930 WDR64 intron −1,292
— 0.085 2 52,543,917 ASB3 flanking_3UTR −1,206,705
— 0.260 3 183,922,829 ATP11B upstream 71,156
— 0.333 5 10,186,704 FAM173B downstream 92,734
— 0.092 7 155,365,705 SHH upstream 67,977
— 0.211 10 22,972,154 PIP4K2A intron 0
— 0.466 15 76,294,371 ACSBG1 intron −6,872
−0.208 0.338 17 53,517,495 DYNLL2 intron −1,452
0.222 0.190 18 64,544,220 TXNDC10 flanking_5UTR −10,887
−0.259 0.165 19 24,014,626 ZNF254 upstream 47,190
−0.245 0.163 19 24,032,745 ZNF254 upstream 29,071
0.05. The hazard ratio (HR) > 1 means that patients carrying the minor allele
d with higher IC50 values in our LCLs, i.e., r-value > 0. After comparing the
f 11 SNPs showed concordant association directions between the two
rs11629576 and rs11079337.
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taxel IC50 in LCLs and overall survival of lung cancer
patients. As shown in Additional file 1: Figure S1, imputed
SNPs were found to have p-values of association with pacli-
taxel IC50 < 10-3 in the region 200 kb up-/downstream of
SNPs rs1778335, rs2662411, rs7260598, rs17304569 and
rs7519667. However, none of the imputed SNPs showed a
stronger association with paclitaxel IC50 than did the
observed SNPs.
SNP-expression association analysis in LCLs
SNPs might influence paclitaxel response through the
regulation of gene expression in a cis-regulation manner.
Therefore, we limited our SNP-Expression analyses to
11 genes which encompassed the 8 SNPs of interest
noted previously by being within 200 kb of the location
of the genes. We further excluded expression probes
that were deemed not to be expressed, defined as an ex-
pression level of less than 50. None of the SNPs which
had p-values for association with paclitaxel IC50 of < 10-3
were found to be associated with this set (possibly cis
regulating) of expression probes (data not show).
Integrated SNP-miRNA-mRNA expression association
analysis in LCLs
In addition to the direct effect of SNP on gene expression,
SNP might alter gene expression through influence on
miRNA expression [31]. We further performed the inte-
grated SNP-miRNA-expression association analysis using
these 8 SNPs, expression of 11 genes and 226 microRNAs.
SNP rs2662411, close to gene CMBL, was associated with
miRNA expression of hsa-miR-584 with p-value =
3.05 × 10-5 (r-value = 0.254). The hsa-miR-584 was also
associated with CMBL mRNA levels with p-value = 7.46 ×
10-4 (r-value = 0.301). Similarly, SNP rs1778335, close to
gene PIP4K2A, was associated with the expression of hsa-
miR-1468 with p-value = 1.57 × 10-3 (r-value = 0.194), and
this microRNA was associated with mRNA expression of
PIP4K2A with p-value = 8.24 × 10-3 (r-value = −0.267).
SiRNA screening in lung cancer cell lines
As shown in Table 1, except for paclitaxel, these 874
lung cancer patients were also treated with one or sev-
eral of the following drugs: platinum compounds, gemci-
tabine, EGFR inhibitors or etoposide. Although the
genotyped SNPs were selected based on their association
with taxane IC50 values in LCLs, the SNP effects on
lung cancer overall survival might be influenced by other
treatments. To further validate the association results,
we also investigated mechanisms by which those 8 SNPs
might have an effect on paclitaxel response. One of the
mechanisms by which SNPs might affect phenotypes is
through their influences on transcription regulation in
either a cis or a trans- manner. Unfortunately, we didnot have enough power to assess the trans-regulation.
Although none of the 8 SNPs showed a significant cis ef-
fect, there could also be other SNPs in LD with these 8
SNPs that we did not genotype or SNPs with low allele
frequencies that could. Therefore, we tested the possible
effect of the 11 genes close to those 8 SNPs on drug re-
sponse by performing knockdown experiments in a
SCLC cell line, H196, and a NSCLC cell line, A549, to
determine if changing gene expression could influence
paclitaxel-induced cytotoxicity. As shown in Figure 3
and Table 3, MTS assay indicated that knockdown of
PIP4K2A, CCT5, CMBL, EXO1, KMO and OPN3, which
were close to SNPs rs1778335, rs2662411 and rs7519667,
significantly desensitized paclitaxel-induced cytotoxicity in
the SCLC cell line H196, and those 3 SNPs were also asso-
ciated with SCLC overall survival with p-value < 0.05
(Table 2). In addition, in the NSCLC cell line, A549,
knockdown of the genes, CHML and KMO, which were
close to rs7519667, also had a significant effect on pacli-
taxel cytotoxicity.
Discussion
Taxanes, including paclitaxel and docetaxel, are
microtubule-stabilizing anticancer agents commonly
used in the treatment of SCLC and NSCLC. Large inter-
individual variation in taxane response has been
observed in lung cancer patients in both efficacy and
toxicities associated with taxane, such as peripheral
neuropathy [32,33]. This large variation is caused by
many different factors, including: tumor genetics, host
genetics as well as the microenvironment [34]. Many
previous studies have demonstrated that germline gen-
etic polymorphisms can play a significant role in indi-
vidual variability in taxane-induced efficacy and toxicity
[9-13,15-18].
In order to understand biological mechanisms under-
lying the variation in response to taxane and to identify
novel biomarkers which might be helpful for individua-
lized taxane chemotherapy, we performed pharmacoge-
nomic studies of paclitaxel and docetaxel in 276 LCLs,
followed by association studies of candidate SNPs identi-
fied during the analysis in LCLs using DNA samples
from NSCLC and SCLC patients treated with paclitaxel.
We then performed functional studies of candidate
genes by siRNA knockdown in lung cancer cell lines. In
this study, we mainly focused on genes that might influ-
ence the mechanism of drug action, i.e., pharmaco-
dynamics, as genes involved in taxane pharmacokinetic
pathways, such as CYP2C8, CYP3A4/A5, which have
been well studied in previous taxane pharmacogenomic
studies, were not highly expressed in our LCLs.
Genome-wide analyses were performed using 1.3 mil-
lion genome-wide SNPs and paclitaxel or docetaxel IC50
values for 276 LCLs. The analyses resulted in the
Figure 3 siRNA screening of candidate genes by MTS assay in lung cancer cell lines. Data are shown for 7 of the 11 candidate genes that
were functionally validated in a SCLC cell line, H196, and an NSCLC cell line, A549, by MTS assay after knockdown with specific siRNA pools. (Red)
Data for negative control siRNA; (blue) data for specific siRNAs. “Significance” was defined as a gene with a significant change in apparent area
under the curve (AUC) in comparison with control siRNA as indicated by the p-values. For those genes with significant change in paclitaxel
response, at least three independent experiments were performed in triplicate. Error bar represents standard error of the mean (SEM) for all of the
experiments. (A) Candidate gene symbols. (B) qRT-PCR. The y-axis indicates relative gene expression after siRNA knockdown when compared with
negative control siRNA. (C) MTS assays. The x-axis indicates the log transformed paclitaxel dose, and the y-axis indicates proportion survival after
drug treatment.
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Table 3 siRNA screening of 11 candidate genes by MTS assay
SNP Basis for selection MTS assay
SNP vs paclitaxel and/or docetaxel
IC50 in LCLs
SNP vs survival in SCLC
patients





(p < 10-3) (p < 0.05) (p < 0.05) H196 A549




rs2700868 Yes Yes ATP11B — —
rs2662411 Yes Yes CCT5 Yes —
CMBL Yes —
rs1106697 Yes Yes Yes RBM33 — —
rs1778335 Yes Yes PIP4K2A Yes —
rs17079623 Yes Yes TMX3 — —
rs17304569 & rs7260598 Yes Yes ZNF254 — —
“Yes” under “Basis for selection” indicates individual candidate genes with the p-value listed. For the MTS assay, “Yes” indicates that knockdown of the gene
altered taxane cytotoxicity when compared with control siRNA. All of the experiments with significant changes were performed in triplicate and were replicated at
least three times.
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associated with cytotoxicity phenotypes for two taxanes
(Figure 2 and Additional file 1: Tables S1–S3). Although
none of the SNPs maintained statistical significance after
Bonferroni correction, 147 and 180 SNPs had p-values
for association with paclitaxel or docetaxel IC50 of
< 10-4, and 76 SNPs overlapped between the two tax-
anes with p-values < 10-3. A previous GWAS from an
ongoing phase III clinical trial, CALGB 40101, identified
3 top SNPs located in the EPHA5, FGD4 and NDRG1
genes that were associated with paclitaxel-induced per-
ipheral neuropathy, although none reached genome-
wide significance [18]. In our study, 3 SNPs located 200-
300 kb upstream of EPHA5 genes and 1 SNP ~14 kb up-
stream of NDRG1 were also found to be associated with
paclitaxel IC50 values with p-value < 10-3 in LCLs, but
not with docetaxel IC50. Therefore, these SNPs were not
included in the subsequent genotyping study with lung
cancer patient samples based on our selection criteria.
Like all model systems, the LCL model system has
limitations. The variation of taxane response in LCLs
might be influenced by EBV transformation-induced cel-
lular changes and non-genetic factors such as cell
growth rate or baseline ATP levels [35-37]. To further
test whether any of these candidate SNPs might be asso-
ciated with overall survival for lung cancer patients trea-
ted with taxanes, we genotyped the 147 top SNPs
associated with paclitaxel IC50 and 76 SNPs which over-
lapped between the two taxanes in LCLs using DNA
samples from 76 SCLC and 798 NSCLC patients after
paclitaxel-based chemotherapy. In this study, instead of
specific taxane response outcomes, overall survival was
used as the clinical phenotype. Therefore, the associationresults could be affected by many other factors, such as
histology, stage, performance and treatment. In order to
adjust for those confounding factors, Cox regression
analysis was performed to test the effect of clinical cov-
ariates on overall survival, including age at diagnosis,
gender, smoking status, disease stage, and treatment. As
a result, disease stage was included in the final multivari-
ate Cox-regression model as it was significantly asso-
ciated with the overall survival of lung cancer patients.
That association study identified 8 SNPs that were
associated with SCLC or NSCLC overall survival with p-
values < 0.05, although none of the SNPs were statisti-
cally significant after Bonferroni correction (Table 2).
The statistical power for association with overall survival
of SCLC patients was low. Therefore, we did functional
studies by using siRNA knockdown, followed by MTS
assays, in a SCLC cell line, H196, and a NSCLC cell line,
A549, for 11 candidate genes chosen based on their
proximity to the 8 SNPs and their expression levels in
LCLs. Knockdown of PIP4K2A, CCT5, CMBL, EXO1,
KMO and OPN3, 6 genes that were close to the 3 SNPs
(rs1778335, rs2662411 and rs7519667) associated with
SCLC overall survival, significantly desensitized H196
cells to paclitaxel (Figure 3). Knockdown of CHML and
KMO, two genes that were close to rs7519667, also had
a significant effect on paclitaxel response in A549 cells
(Figure 3). Integrated SNP-miRNA-mRNA expression
association analysis indicated that SNPs rs2662411
and rs1778335 were associated with mRNA expression
of CMBL or PIP4K2A through hsa-miR-584 or hsa-
miR-1468. In our study, SNP rs2662411 was associated
with higher miRNA expression of hsa-miR-584 (r-value
= 0.254, p-value = 3.05 × 10-5), which was associated with
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p-value = 7.46 × 10-4); in SCLC cell line, knockdown of
CMBL caused paclitaxel resistance; those results were
consistent with the association of SNP rs2662411 with
lower paclitaxel IC50 in LCLs (r-value = −0.245, p-value =
6.36 × 10-5) and better overall survival in SCLC patients
(HR = 0.666, p-value = 0.039) (Table 1). Similarly, in LCLs
SNP rs1778335 was associated with higher expression
of hsa-miR-1468 (r-value = 0.194, p-value = 1.57 × 10-3),
which was associated with lower expression of PIP4K2A
(r-value = −0.267, p-value = 8.24 × 10-3); in SCLC cell line
knockdown of PIP4K2A resulted in paclitaxel resistance;
those results were consistent with the association of SNP
rs1778335 with higher paclitaxel IC50 in LCLs (r-value =
0.248, p-value = 6.04 × 10-5) and worse overall survival in
SCLC patients (HR = 1.602, p-value = 0.019). However, no
corresponding miRNA binding sites was found in either
CMBL or PIP4K2A from microRNA public database, fu-
ture experiment will be performed to validate these
results.
Previous studies indicated that an individual miRNA
could affect expression of multiple genes and an individual
mRNA might also be regulated by multiple miRNAs,
which was mainly through miRNA targeting 30 untrans-
lated region (30-UTR) of mRNA [38]. SNPs located in the
miRNA-coding genes or miRNA-binding site of mRNA
could influence the pathogenesis of disease or drug re-
sponse through affecting the biogenesis of miRNA or
binding of miRNA with mRNA [31,39]. SNP 829C > T in
the 30UTR of dihydrofolate reductase (DHFR), which was
located in the miR24 microRNA binding site, has been
reported that it caused the loss of miR24 function and
resulted in DHFR overexpression and methotrexate
(MTX) resistance [40]. CMBL gene encoded carboxy-
methylenebutenolidase homolog (CMBL), which was a
cysteine hydrolase of the dienelactone hydrolase family
and was involved in the metabolism of prodrug olmesar-
tan medoxomil [41]. The homology of CMBL protein
among human, mouse and rat were more than 80%. In
human CMBL was widely expressed in many tissues, espe-
cially in liver and intestine [41]. A proteomic study by
Yang et al. found that CMBL was an H2AX-interacting
protein [42], which suggested that CMBL might be
involved in cellular responses to DNA damage and DNA
repair.
PIP4K2A gene encoded phosphatidylinositol-5-
phosphate 4-kinase, type II, alpha (PtdIns5P 4-kinase α).
As a major type of type II PtdIns5P 4-kinases, it was
involved in the conversion of phophatidylinositol-
5-phosphate (PtdIns5P) into phosphatidylinosital-4,
5-bisphosphate [PtdIns(4,5)P2] [43]. Since the cellular level
of phophatidylinositol-4-phosphate (PtdIns4P), which was
another source to form PtdIns(4,5)P2, was approximately
ten times higher than that of PtdIns5P, the major functionof type II PtdIns5P 4-kinases was most probably to regulate
the level of PtdIns5P [44,45]. There were three mammalian
isoforms for type II PtdIns5P 4-kinases: α, β and γ [46].
PtdIns5P 4-kinase α was located in both cytoplasm and nu-
cleus, and could form homodimer or heterodimer with
PtdIns5P 4-kinase β or γ [45,47]. In vitro assays indicated
that PtdIns5P 4-kinase α had the highest enzyme activity
[43], and knockdown of PtdIns5P 4-kinase α significantly
enhanced the tyrosine-kinase regulated PtdIns5P produc-
tion [48]. Although no obvious phenotype was found for
knockout of PtdIns5P 4-kinase α, the double knockout of
PtdIns5P 4-kinase α and β was found to be embryonic le-
thal [43]. Several previous studies also demonstrated that
PtdIns5P was a second messenger in cellular signaling,
PtdIns5P could activate PI 3-kinase/Akt pathway [49] and
protect Akt from dephosphorylation through inhibition of
PP2A phosphatise [50], and in nucleus PtdIns5P could
bind to inhibitor of growth protein-2 (ING2) and regulate
p53-mediated response to DNA damage [51]. However,
the mechanisms of those two genes involved in paclitaxel
response still remain unknown, further mechanistic studies
will be required.
For the other four genes (CCT5, EXO1, KMO and
OPN3) that were close to the 2 SNPs (rs2662411 and
rs7519667), our association analyses and knockdown
experiments suggested a potential function in paclitaxel
response. However, no significant cis relationship was
found by either SNP-expression association analysis or
integrated SNP-miRNA-mRNA expression association
analysis. One possibility is that there might be rare var-
iants in LD with those 2 SNPs that might be the causal
SNPs regulating gene expression. In addition, the effect
of SNP on gene expression was tissue specific. There-
fore, future deep resequencing of these regions might
help to identify rare variants to test this hypothesis, and
we also need to perform the SNP-expression association
analysis using lung cancer tissue samples.
Conclusions
In summary, our GWAS in LCLs, together with transla-
tional studies with DNA samples from lung cancer
patients, followed by functional studies in lung cancer cell
lines showed that 6 genes, PIP4K2A, CCT5, CMBL, EXO1,
KMO and OPN3, genes that are close to 3 SNPs associated
with SCLC overall survival (rs1778335, rs2662411 and
rs7519667), significantly altered paclitaxel cytotoxicity in
the SCLC cell line, H196. SNPs rs2662411 and rs1778335
might regulate mRNA expression of CMBL and PIP4K2A
through influence on miRNA expression of hsa-miR-584
or hsa-miR-1468. These results provide additional insight
into genes that may contribute to variation in response to
taxanes and genetic variations that may be associated with
overall survival of paclitaxel-treated lung cancer patients.
We acknowledge that the patient population used in the
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overall survival, could be influenced by multiple factors
other than the treatment. Although we adjusted for all the
known factors during the association studies, we cannot
exclude the possibility that the genetic variations identified
might be prognostic factors rather than taxane predictive
factors. Further confirmation of these findings using spe-
cific taxane response outcome in additional homogeneous
patient cohorts would seem to be warranted.
Additional file
Additional file 1: Figure S1. Imputation analysis for 8 SNPs associated
with both paclitaxel IC50 in LCLs and overall survival in lung cancer
patients. SNPs within 200 kb up-/downstream of those 8 SNPs were
imputed. Black circle indicate SNPs observed by genotyping, while red
triangle indicate imputed SNPs. The y-axis represents –log10(p-value) for
the association of each SNP with paclitaxel IC50, and the x-axis
represents the chromosome location of the SNPs. Table S1. Top 1415
SNPs that were associated with paclitaxel IC50 with p-values < 10-3 and
top 147 SNPs that were significantly associated with paclitaxel IC50
values with p-values < 10-4. R values represent correlation coefficients for
the associations. Table S2. Top 1736 SNPs that were associated with
docetaxel IC50 with p-values <10-3 and top 180 SNPs were significantly
associated with docetaxel IC50 values with p-values <10-4. R values
represent correlation coefficients for the association. Table S3. 76 SNPs
were associated with IC50s for both paclitaxel and docetaxel with p-
values < 10-3. Table S4. Results of Cox regression analysis with overall
survival for either SCLC or NSCLC patients. The SNPs associated with
overall survival with p-value < 0.05 are highlighted.
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